Pcn149 - Cost-Effectiveness of Brca1/2 Mutation Profiling to Target Olaparib Use in Patients With Metastatic Breast Cancer in Japan

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.232
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Performance of BRCA1/ 2 Mutation Prediction Models in Male Breast Cancer Patients

Clinical Genetics
Genetics
2017English

Cost Effectiveness of the Cancer Prevention Program for Carriers of the BRCA1/2 Mutation

Revista de Saude Publica
MedicineEnvironmentalPublic HealthOccupational Health
2018English

Cost Effectiveness of Molecular Profiling for Adjuvant Decision Making in Patients With Node-Negative Breast Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2014English

Lurbinectedin Is Active in Patients With BRCA1/2 Mutant Breast Cancer

Cancer Discovery
Oncology
2018English

Cost-Effectiveness Analysis of Annual Breast Cancer Screening in Japan.

Nihon Nyugan Kenshin Gakkaishi (Journal of Japan Association of Breast Cancer Screening)
1997English

Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2016English

Body Weight and Risk of Breast Cancer in BRCA1/2 Mutation Carriers

Breast Cancer Research and Treatment
Cancer ResearchOncology
2010English

What Is the Best Risk-Reducing Decision for Breast Cancer Patients With BRCA1/2 Mutation?

Archives of Breast Cancer
2018English

BRCA1 (185delAG) Mutation Among Egyptian Breast Cancer Female Patients

Journal of High Institute of Public Health
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy